Modality
ASO
MOA
STINGag
Target
TYK2
Pathway
T-cell
NarcolepsyRB
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Jun 2029
Phase 1Current
NCT07732855
1,425 pts·RB
2020-06→2029-06·Active
NCT04665613
1,527 pts·RB
2023-03→2026-11·Recruiting
2,952 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-248mo awayPh2 Data· RB
2029-06-213.2y awayPh2 Data· RB
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2026-11-24 · 8mo away
RB
Ph2 Data
2029-06-21 · 3.2y away
RB
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07732855 | Phase 1/2 | RB | Active | 1425 | DAS28 |
| NCT04665613 | Phase 1/2 | RB | Recruiting | 1527 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |